Boston Scientific Leads $175M Investment in 4C Medical for Heart Valve Trial

Boston Scientific has spearheaded a $175 million investment in 4C Medical Technologies to support the pivotal trial of its transcatheter mitral valve replacement (TMVR) device in the U.S. and Europe. The funding round, which included new and existing investors, significantly boosts 4C Medical’s financial backing as it advances its minimally invasive heart disease therapies. The trial, targeting 450 patients with mitral regurgitation, aims to evaluate the device’s effectiveness for individuals unsuitable for surgery or alternative transcatheter treatments.

Boston Scientific’s investment aligns with its strategy of funding and acquiring promising medtech startups. With nearly 50 companies in its venture portfolio, Boston Scientific frequently identifies M&A opportunities through such investments. 4C Medical's trial, set for primary completion in 2029, positions the company for potential commercialization, following a similar path to other Boston Scientific-backed innovations in the structural heart disease space.